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Abstract
Tissue kallikreins (KLKs), in particular KLK5, 7 and 14 are the major serine proteases in the
skin responsible for skin shedding and activation of inflammatory cell signaling. In the nor-
mal skin, their activities are controlled by an endogenous protein protease inhibitor encoded
by the SPINK5 gene. Loss-of-function mutations in SPINK5 leads to enhanced skin kalli-
krein activities and cause the skin disease Netherton Syndrome (NS). We have been devel-
oping inhibitors based on the Sunflower Trypsin Inhibitor 1 (SFTI-1) scaffold, a 14 amino
acids head-to-tail bicyclic peptide with a disulfide bond. To optimize a previously reported
SFTI-1 analogue (I10H), we made five analogues with additional substitutions, two of which
showed improved inhibition. We then combined those substitutions and discovered a vari-
ant (Analogue 6) that displayed dual inhibition of KLK5 (tryptic) and KLK7 (chymotryptic).
Analogue 6 attained a tenfold increase in KLK5 inhibition potency with an Isothermal Titra-
tion Calorimetry (ITC) Kd of 20nM. Furthermore, it selectively inhibits KLK5 and KLK14 over
seven other serine proteases. Its biological function was ascertained by full suppression of
KLK5-induced Protease-Activated Receptor 2 (PAR-2) dependent intracellular calcium
mobilization and postponement of Interleukin-8 (IL-8) secretion in cell model. Moreover,
Analogue 6 permeates through the cornified layer of in vitro organotypic skin equivalent cul-
ture and inhibits protease activities therein, providing a potential drug lead for the treatment
of NS.
Introduction
The Stratum Corneum forms the outermost layer of human skin and is composed of non-via-
ble flattened corneocytes stacked in multiple layers. With the extracellular space filled by lipids,
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connected to insoluble cross-linked proteins underneath the plasma membrane, it becomes an
effective barrier to many substances including water. Adjacent corneocytes are further con-
nected by the cell-cell adhesion complex known as corneodesmosomes, comprising specialized
proteins such as Desmoglein 1 and Desmocollin 1 [1]. In the normal skin, proteolysis of those
structural proteins results in breakdown of corneodesmosomes leading to corneocyte detach-
ment and controlled skin shedding i.e. desquamation [2]. The secreted proteases responsible
for corneodesmosomedegradation are Kallikrein 5 (KLK5) and Kallikrein 7 (KLK7) [3]. These
are serine proteases in the 15-membered human tissue kallikreins family of which KLK5 is
tryptic and KLK7 is chymotryptic. Together with KLK14, these skin kallikreins participate in a
proteolytic cascade and play a major role in desquamation [4]. Moreover, KLK5 and KLK14
have been implicated in skin inflammation by activating the PAR-2 pathway leading to release
of inflammatory cytokines including IL-8 [5–7].
Activity of the aforementioned kallikreins is specifically controlled by their endogenous
inhibitor Lympho-Epithelial Kazal-Type related Inhibitor (LEKTI), encoded by the gene
SPINK5 [8]. Loss-of-functionmutations in SPINK5 cause the rare genetic skin diseaseNether-
ton Syndrome (NS) [9]. As a result of unregulated skin kallikreins activity and excessive skin
desquamation, NS patients suffer from scaly skin, atopic manifestation, growth retardation and
dehydration, which can be lethal for infants. There is no approved drug hitherto to specifically
treat NS. Treatment is currently symptomatic only, based on emollients and topical steroids,
with reports of calcineurin inhibitors [10], immunoglobulin replacement [11], anti-Tumor
Necrosis Factor α antibody Infliximab [12], and phototherapy [13]. Most recently, a specific
NS treatment based on gene therapy has also been under development [14].
Direct inhibition of skin kallikreins by synthetic inhibitors is an attractive potential therapy
for NS as it could target the underlying abnormality. This has led to the development of inhibi-
tors ranging from synthetic LEKTI protein domain D6 [15] for KLK5, small organic molecules
[16], depsipeptides [17] and an SFTI-1 analogue [18] for KLK7. Recently, the focus has been
on selectivemultiple kallikrein inhibitors targeting KLK5, KLK7 and KLK14. For example,
dual inhibition of KLK5 and KLK7 by isomannide-basedpeptidomimetics [19] and derivatives
of 1,2,4-triazole [20], coumarin-3-carboxylate [21] and benzoxazinone [22] multiple kallikrein
inhibitors have been described. Besides these small organics, a set of SFTI-1 analogues with 6
out of its 14 amino acid substituted showed multiple kallikrein inhibition and selectivity against
other unrelated serine proteases [23].
KLK5 is a key player in the pathogenesis of NS [24] and an initiator of proteolytic cascade
in the skin epidermis as it is able to activate itself, pro-KLK7 and pro-KLK14 [25]. We there-
fore aimed to develop a specific KLK5 inhibitor by making analogues of the previously
reported SFTI-1 analogue I10H [26], which has the isoleucine substituted with histidine on
position 10 of the SFTI-1 sequence. Though serine proteases have a substrate specificity bind-
ing pocket, it only crudely distinguishes them between trypsin-like, chymotrypsin-like or
elastase-like. Their refined substrate specificity probably arises from the additional specific
interactions formed outside of the binding pocket over a large surface area. Developing a spe-
cific serine protease inhibitor is therefore a similar task to developing protein-protein interac-
tion inhibitors as they often require molecules that form multiple interactions over a large
and flexible surface area with the target. This is easily achieved by natural specific protein pro-
tease inhibitors but a difficult problem for small organic molecules to solve. Covering large
interaction surface area without becoming non-druglike is more amenable to macrocyclic
molecules e.g. SFTI-1.
There are currently two main strategies for making SFTI-1 (Fig 1, Panel A), for both of
which the backbone cyclization step is yield-determining. First is the use of acid-labile resins of
which the linear peptide is cyclizedwhile its sidechains remain protected [27]. On-resin
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cyclization followed by disulfide formation with selective deprotection of the cysteine residues
has also been described [28]. We employed the second strategy native chemical ligation involv-
ing intramolecular reaction of a peptide thioester with its terminal cysteine [29]. To make the
thioester, we exploited the mechanism of N-S acyl transfer on cysteine (Fig 1, Panel B), which
offers a convenient reaction setup and does not require special resins or amino acids. This
method gives the best yield of SFTI-1 analogues when the cysteine is preceded by a glycine or
histidine residue (“HC”) [30]. Our previous results showed that a histidine instead of glycine
substitution on position 10 of the native SFTI (SFTI-1) sequence provided a stronger KLK5
inhibitor [26]. We therefore started by making a single substitution (H-GRCTKSIPPHCFPD-
OH, I10H) and rearrangement of the SFTI-1 sequence H-GRCTKSIPPICFPD-OH to H-
CFPDGRCTKSIPPHC-OH for thioester formation (Fig 1, Panel B).
The potency of KLK5 inhibition by I10H was first compared to a few reference compounds
using a fluorescence-based enzyme assay. I10H is 80 times more potent than p-aminobenzami-
dine (IC50 0.76 vs. 60.45 μM) and retained a similar potency to that of native SFTI. To optimize
I10H in terms of potency and selectivity, six more of its analogues were made. Here we report
a novel triple substituted SFTI-1 variant (Analogue 6) with bifunctional protease inhibition
properties. Analogue 6 is a potent KLK5 inhibitor as determined by enzyme inhibition assay,
ITC and in vitro cell-based assay. It also displayed multiple kallikrein inhibition with
Fig 1. Chemical Structure of Sunflower Trypsin Inhibitor-1 and the “HC” Synthetic Strategy. Chemical structure of native
SFTI (A) and the synthetic strategy for “HC” analogue synthesis (B) are shown. Amino acid residues and their position in the native
peptide sequence are labelled in letters and numbers respectively. The P1 residue which will fit into the enzyme substrate binding
pocket is lysine located at position 5 with the scissile bond indicated by an arrow. The side of SFTI-1 that forms direct contact with
the enzyme and the non-contacting side are segregated by the red line.
doi:10.1371/journal.pone.0166268.g001
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preference for KLK5 and KLK14 over KLK7, KLK8, matriptase and human plasma plasmin.
The biological function of Analogue 6 was further verified by its ability to delay KLK5-induced
PAR-2 dependent IL-8 release in keratinocytes and inhibit skin proteases in in vitro skin equiv-
alent cultures.
Results
Design, Synthesis and Proteases Inhibition of I10H Analogues
Inhibition of KLK5 by I10H as well as zinc, p-aminobenzamidine and native SFTI was first
tested using the fluorogenic substrate Boc-VPR-AMC (S1 Table and S1 Fig). I10H (IC50
0.76 μM) showed a four and eighty fold potency increase compared to the known KLK5 inhibi-
tor zinc (IC50 2.94 μM) and the unspecific trypsin-like protease inhibitor p-aminobenzamidine
(IC50 60.45 μM) respectively. The IC50 of zinc is in a comparable range to that of its previously
reported Ki value [31]. Compared to that of native SFTI (IC50 0.30 μM), the potency is however
reduced slightly by twofold. Overall, I10H remained a relatively strong KLK5 inhibitor and so
we continued with the development I10H analogues.
The crystal structure of KLK5 from the Protein Data Bank (PDB) ID 2PSY [31] was super-
imposed onto bovine trypsin complexed to native SFTI (PDB ID ISFY) [32] to illustrate poten-
tial SFTI-KLK5 interactions (Fig 2). With amino acid sequence alignment between all other
kallikreinmembers and matriptase, a few KLK5 residues that I10H could target specifically
were identified (Table 1). The I10H analogues listed in Table 1 were synthesized and tested by
fluorogenic assay with Boc-VPR-AMC as the substrate (Table 2). Analogue 1 and 2 showed a
significant improvement on KLK5 inhibition compared to that of I10H. Changing the isoleu-
cine to lysine (Analogue 5) severely hampered KLK5 inhibition. Although Analogues 3 and 4
were not stronger KLK5 inhibitors, our synthetic strategy consistently gave a final yield of
around 20%.
Based on the results in Table 2, a sixth analogue (Analogue 6) incorporating the K5R and
F12W substitution (GRCTRSIPPHCWPD) was made. The synthesis again offered a final yield
of 24% giving us 10.8 mg of the pure inhibitor from 46.7 mg of linear peptide. The inhibition of
this triple substituted SFTI-1 variant along with its predecessors (I10H and Analogue 2) and
native SFTI were tested on ten serine proteases (Table 3), seven trypsin-like, two elastase and
one chymotrypsin-like (KLK7). Human neutrophil elastase and porcine pancreatic elastase 1
were not inhibited by any of the SFTI-1 analogues. Human plasma kallikreinwas only inhib-
ited slightly by Analogue 6 at 10 μM.
Natural selective protease inhibition is illustrated by the inhibitory profile of native SFTI
(Table 3). Native SFTI inhibitedmost strongly on bovine trypsin, KLK14 and plasma plasmin
over KLK5, KLK8 and matriptase. It is a very poor KLK7 inhibitor and was unable to inhibit
plasma kallikrein and the two elastases. Changing the isoleucine at position 10 to histidine on
the SFTI-1 sequence not only reduced inhibition of KLK5 by two folds, but to different extents,
for all the tested tryptic and chymotryptic proteases. The I10H substitution was most intolera-
ble to KLK14 with an almost 20 fold potency drop compared to native SFTI. In contrast, the
additional F12W substitution (Analogue 2) salvaged the adverse effect of I10H and afforded a
better enzyme inhibitor.
With the third substitution K5R (Analogue 6), a KLK5 inhibitor ten times more potent than
I10H (Fig 3) was attained. Analogue 6 is also a strong inhibitor for bovine trypsin, and KLK14
but selective against the other seven tested proteases. Interestingly, Analogue 6 displayed chy-
motryptic inhibition against KLK7 with a potency near to that of its inhibition on the other
tryptic enzymes. This is a major improvement as the binding affinity of native SFTI towards
chymotrypsin is of around four orders of magnitude weaker than trypsin [35].
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Dissociation Constants (Kd) by Isothermal Titration Calorimetry
In addition to enzyme assays, we determined the binding affinity (Kd) and characterized the
thermodynamic binding profile (S2 Table) of I10H, Analogue 1, 2 and 6 for KLK5. Their iso-
therms demonstrated the binding of these cyclic peptides to KLK5 was endothermic and entro-
pically driven (Fig 4). The binding stoichiometry is in agreement with the literature, which was
found to be approximately 1:1. In good agreement with the Ki values from Table 3, the deter-
mined ITC Kd for I10H, Analogue 1, 2, and 6 are 485 nM (Ki = 478 nM), 115nM, 96 nM
(Ki = 91 nM) and 20 nM (Ki = 51 nM) respectively. The tenfold improved potency from I10H
to Analogue 6 in the enzyme inhibition assay is depicted by an increase in binding affinity of
around 25 times. These binding constants were determined in phosphate buffered saline (PBS)
solution (pH 8.0) at 25°C. However, when tested at the same temperature and similar ionic
strength but a different pH (pH 5.5) buffered using 2-(N-morpholino) ethanesulfonic acid
Fig 2. Regions Targeted by I10H Analogues Outside of the KLK5 Substrate Binding Pocket. Molecular
docking has revealed several regions (blue, green and red) of KLK5 outside the substrate specificity binding
pocket (magenta) that SFTI-1 (shown in cylinders) could engage for extended specific interactions. Surface
display of the model was generated by CCP4MG [34].
doi:10.1371/journal.pone.0166268.g002
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(MES), no enthalpy change (ΔH) was observed (data not shown). Unless ΔHwas inherently
equal to zero under such condition, these SFTI-1 analogues do not bind to KLK5 at pH 5.5.
Prevention of KLK5-Induced Intracellular Calcium Mobilization
As well as being in the G-protein Coupled Receptor family, PAR-2 is naturally activated by the
tethered ligand mechanism [36]. It has been demonstrated that PAR-2 can be activated by
KLK5 in keratinocytes [5]. One of the events that take place upon PAR-2 activation is intracel-
lular calciummobilization. This can be measured by fluorogenic calcium-binding dyes, as the
fluorescence increases during calcium release and drops back to base level due to re-uptake.
The potential biological activity of SFTI-1 and its analogues were further ascertainedby its abil-
ity to block KLK5-induced PAR-2 activation in the keratinocyte cell line N-tert. To ensure that
the PAR-2 activated intracellular calciummobilization apparatus was operational in the cell
line, the cells were first challenged with the PAR-2 agonist peptide H-SLIGKV-NH2 (S4 Fig).
Table 1. Design of I10H Analogues.
KLK5 Motifs a I10H Analogues b Modification Potential Interactions
HPGHS (green region Fig 2) GRCTKSIPPHCYPD F!Y (F12Y) hydrogen bond between hydroxyl of tyrosine and nitrogen of
histidine
HPGHS (green region Fig 2) GRCTKSIPPHCWPD F!W (F12W) π-π stacking between tryptophan and histidine or hydrogen-π
interaction
PNQLY (blue region Fig 2) GRCTKSKPPHCFPD I!K (I7K) hydrogen bond between NH of lysine and C = O of asparagine side
chain
SWGDYP (red region Fig 2) NRCTKSIPPHCFPD G!N (G1N) hydrogen bond between C = O of aspartate and NH of asparagine
side chain
The Substrate Pocket (magenta region Fig 2) GRCTRSIPPHCFPD K!R (K5R) Substrate binding pocket of KLK5 is predicted to have preference
for arginine [33]
a Letters in bold are the amino acid residues that were expected to form the interactions.
b Letters in bold are the additional substitutions on the I10H sequence.
doi:10.1371/journal.pone.0166268.t001
Table 2. I10H Analogues Synthetic Yields and Their KLK5 Inhibition.
Analogues Sequence a Molecular Weight Isolated yield from linear
precursor /%
Boc-VPR-AMC IC50
(N = 3)/nM b
Inhibitory Constant
(Ki)/nM
I10H GRCTKSIPPHCFPD 1537.8 (calculated) 1538.3
(measured)
19 352 ±144 322
1 (K5R_I10H) GRCTRSIPPHCFPD 1565.8 (calculated) 1566.2
(measured)
24 65 ±10 60
2 (I10H_F12W) GRCTKSIPPHCWPD 1576.8 (calculated) 1577.2
(measured)
25 36 ±15 33
3 (G1N_I10H) NRCTKSIPPHCFPD 1594.8 (calculated) 1595.2
(measured)
25 511 ±86 467
4 (I10H_F12Y) GRCTKSIPPHCYPD 1553.8 (calculated) 1554.1
(measured)
19 334 ±31 305
5 (I7K_I10H) GRCTKSKPPHCFPD 1552.8 (calculated) 1553.2
(measured)
16 c >10,000 >9000
a Letters in bold indicate the additional substitution made to I10H.
b IC50 curves of each tested ligand are displayed in S2 Fig.
c reduced yield due to repeated purification.
doi:10.1371/journal.pone.0166268.t002
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The cells were then challenged with KLK5 alone and a fluorescence peak was also observed
(KLK5 Only, Fig 5). The KLK5 peak had similar peak time to that of the PAR-2 agonist, but
returned to backgroundmuch more slowly. When KLK5 was injected in a mixture containing
SFTI-1 or its analogues to the cells, PAR-2 activation was clearly attenuated. Complete
Table 3. Enzyme Inhibitory Profile of I10H Analogues.
Protease a/nM Substrate a/μM IC50 (N = 3) /nM b
Native SFTI I10H Analogue 1 Analogue 2 Analogue 6
Bovine Trypsin (10) Boc-VPR-AMC (21) 19 ±1 46 ±2 n.d. 20 ±0.2 23 ±1
KLK14 (10) Boc-VPR-AMC (45) 30 ±7 470 ±47 n.d. 85 ±6 24 ±2
KLK5 (10) Boc-VPR-AMC (42) 230 ±3 (Ki = 210) 523 ±11 (Ki = 478) n.d. 100 ±2 (Ki = 91) 56 ±0.5 (Ki = 51)
KLK8 (9) Boc-VPR-AMC (42) 1286 ±251 1683 ±51 n.d. 563 ±14 373 ±31
Matriptase (10) Boc-VPR-AMC (21) 1254 ±57 2244 ±567 n.d. 206 ±10 381 ±12
Human Plasma Plasmin
(24)
Boc-VPR-AMC (42) 24 ±4 161 ±6 n.d. 25 ±1 407 ±8
KLK7 (10) BODIPY_FL (Casein
6.5 μg/mL)
18% inhibition at
11 μM
0% inhibition at
11 μM
2289 ±68 28% inhibition at
11 μM
534 ±29
Human Neutrophil Elastase
(10)
MeOSuc-AAPV-AMC (41) 0% inhibition at
10 μM
0% inhibition at
10 μM
n.d. 0% inhibition at
10 μM
0% inhibition at
10 μM
Porcine Pancreatic
Elastase 1 (46)
MeOSuc-AAPV-AMC (41) 0% inhibition at
10 μM
0% inhibition at
10 μM
n.d. 0% inhibition at
10 μM
0% inhibition at
10 μM
Human Plasma Kallikrein
(14)
Boc-VPR-AMC (42) 0% inhibition at
10 μM
0% inhibition at
10 μM
n.d. 0% inhibition at
10 μM
15% inhibition at
10 μM
a value denoted in bracket is the final assay concentration.
b Fitted IC50 curves (except KLK5) of each tested ligand are displayed in S3 Fig.
n.d.: Not Determined.
doi:10.1371/journal.pone.0166268.t003
Fig 3. Fitted IC50 Curves of KLK5 Inhibition by Native SFTI and Its Analogues. The fitted KLK5 inhibition
IC50 curves including error bars (standard deviation) of each repeated reading (N = 3) for SFTI-1 and its
analogue are shown.
doi:10.1371/journal.pone.0166268.g003
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Fig 4. Fitted Isotherms for Binding of I10H and Its Analogues to KLK5 in 1xPBS at 25˚C. Fitted
isotherms of I10H (A), Analogue 1 (B), Analogue 2 (C) and Analogue 6 (D) are shown. Binding of all tested
cyclic peptides to KLK5 are endothermic and entropically driven.
doi:10.1371/journal.pone.0166268.g004
Skin Tissue Kallikrein Inhibitors Based on SFTI-1 Scaffold
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suppression of intracellular calciummobilization was achieved at inhibitor-to-enzymemolar
ratio of around 4:1, 2:1 and 1:1 for I10H, native SFTI, and Analogue 2 or 6 respectively (Fig 5).
These molar ratios are corroboratory to their comparative IC50 values in Table 3 obtained from
enzyme inhibition assay.
Suppression of KLK5-Induced IL-8 Release
Although Analogue 6 successfully prevented the immediate effect (intracellular calciummobi-
lization) of PAR-2 activation, its ability to control the downstream effect of PAR-2 mediated
cytokine release remained unknown. It has been shown the production of the cytokine IL-8 is
upregulated by PAR-2 activation in different human cell types including keratinocytes [7, 37,
38]. We therefore probed the duration of biological effectiveness of Analogue 6 by determining
its ability to control IL-8 secretion in N-tert cells stimulated with KLK5. IL-8 level has indeed
increased after KLK5 stimulation in N-tert cells at 6 and 24 hours (p<0.01, Fig 6). The increase
Fig 5. Suppression of KLK5-Induced Intracellular Calcium Mobilization by Native SFTI and Its Analogues. Change in relative
fluorescence unit (ΔRFU) was monitored continuously for about 5 minutes after injection of a mixture of KLK5 (774 nM) with various
concentrations of native SFTI or its analogues. KLK5 and the inhibitors were diluted in 1xPBS and the concentration values indicate
their final concentration in the well. For each tested ligand, a positive control (KLK5 Only) and negative control (Inhibitor Only) were
performed to ensure the inhibitor and the diluent does not cause a signal. Total suppression of KLK5-induced intracellular calcium
mobilization was achieved at an inhibitor-to-enzyme ratio of 2:1 for native SFTI (A), 4:1 for I10H (B.) and 1:1 for Analogue 2 (C) and
Analogue 6 (D).
doi:10.1371/journal.pone.0166268.g005
Skin Tissue Kallikrein Inhibitors Based on SFTI-1 Scaffold
PLOS ONE | DOI:10.1371/journal.pone.0166268 November 8, 2016 9 / 22
was however a transient response as there was no statistical difference found in IL-8 level 48
hours after stimulation between the stimulated and unstimulated cells. At a molar excess of 5:1,
Analogue 6 was able to suppress IL-8 increase up to 6 hours (p<0.05) but not 24 hours after
stimulation.
Inhibition of Skin Protease Activity in in vitro Skin Model
To assess protease inhibition of Analogue 6 in skin-like environment, in vitro skin equivalent
cultures were generated using primary human keratinocytes and fibroblasts. The matured cul-
tures were topically treated with Analogue 6 (10 μM) in PBS solution once every day for two
days. Cryosectionsof the treated and untreated skin were subjected to in-situ zymography with
fluorescently labelled casein substrate and examined by fluorescencemicroscopy. Skin protease
activity was shown to be weaker in the epidermis of the treated skin compared to untreated
skin (Fig 7). This indicates Analogue 6 has penetrated the cornified layer of the in vitro grown
skin and inhibited protease activity in the epidermis.
Fig 6. Control of IL-8 Secretion by Analogue 6 in KLK5 Simulated N-tert Skin Cells. Changes in IL-8 level in the cell medium was
monitored 6, 24 and 48 hours after identical cell populations were stimulated with fresh medium (Medium Only), or KLK5 (KLK5 Only,
f/c 300 nM), or KLK5 + Analogue 6 (KLK5 + Analogue 6), or Analogue 6 (Analogue 6 Only, f/c 1515 nM), or 0.2 mM MES (Medium + 0.2
mM MES). All substances were diluted with cell culture medium. Control samples including the medium with MES were used to ensure
that MES which was in the KLK5 protein stock solution did not cause IL-8 level to change. Basal IL-8 level prior to stimulation (0hr pre-
treatment) as well as for unstimulated cells 48hrs after (48hr untreated) were also determined to serve as quality controls. A coefficient
variation of around 11% and 6% for 0hr pre-treatment and 48hr untreated respectively indicates the status of cell populations in each
well was homogenous throughout the experiment. Error bars are standard deviations of IL-8 readings from different wells of cells. N.S.
Not Statistically Significant; * p<0.05; **p<0.01.
doi:10.1371/journal.pone.0166268.g006
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Discussions and Conclusions
One of the major obstacles for bringingmacrocyclic peptide-baseddrugs to the market is the
complexity and cost of manufacturing on a large scale. Here we aimed to develop analogues of
SFTI-1 for the potential treatment of the severe rare genetic skin diseaseNetherton syndrome.
We employed the “HC” apparatus by replacing an isoleucine that precedes the cysteine in the
native SFTI sequence with a histidine (I10H) to synthesize SFTI-1 analogues. The “HC” appa-
ratus consistently offered a final yield of around 20% on all the analogues we have made in an
essentially four-step process (Fig 1, Panel B). The prerequisite of histidine substitution
prompted us to first see its effect on biological activity. We showed by means of enzyme assay
that I10H retained its protease inhibitory activity albeit is a slightly weaker KLK5 inhibitor
than native SFTI.
Equipped with a synthetic strategy (I10H) of good yield without significantly compromising
biological activity, we explored a few I10H analogues. The analogue design was based on
docking studies and purported for a KLK5 specific inhibitor. Two of the five I10H analogues
Fig 7. In-Situ Zymography in Organotypic Skin Culture (OTC). Fluorescence images from in-situ zymography of OTC treated with PBS (A &
B) or Analogue 6 (C & D) are shown. For the negative staining, PBS was applied to the cryosection instead of casein substrate solution (B & D).
Cell nuclei were counterstained with 4’,6-diamidino-2-phenylindole (blue color) and protease activity is signaled by green fluorescence. All images
were obtained in MicroManager (Ver.1.4.21) with an exposure time of 1s and images were processed using ImageJ (Ver.1.46) and finalized by
Adobe Photoshop CS. Brightness and contrast settings were all the same and applied to the entire images. Scale Bar = 200 μm.
doi:10.1371/journal.pone.0166268.g007
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(Analogue 1 & 2) in Table 2 showed an increased inhibition on KLK5. Analogue 5 suffered a
complete loss of activity, which could be the result of taking both isoleucines (I7K_I10H) out
of the native SFTI sequence, or the result of the I7K substitution alone. The latter is likely to be
true because we have shown that I10H substitution did not significantly alter KLK5 inhibition
compared to native SFTI. Moreover, a recent paper showed that KLK5 inhibition was reduced
by 90% with the I7K substitution whilst the other isoleucinewas kept [39].
By combining substitutions of Analogue 1 and 2, Analogue 6 was made and tested along
with native SFTI, I10H, and Analogue 2 on a range of serine proteases (Table 3). None of the
substitutions introduced into the native SFTI sequence significantly altered the bovine trypsin
inhibitory property of the bicyclic peptide. This was not unexpectedbecause changes such as
lysine to arginine and phenylalanine to tryptophan were considered conservative. The most
dramatic change was from isoleucine to histidine and I10H was overall the least potent of the
four inhibitors for the tested enzymes. It should also be pointed out that the IC50 of native SFTI
for bovine trypsin is much higher than the previously reported Ki values of 0.02–0.1 nM [23,
32]. This is because IC50 values are heavily dependent on assay conditions such as the enzyme
concentration [E], substrate concentration at half maximal enzymic rate (Km), assay substrate
concentration [S] and assay temperature. Under optimal assay conditions, IC50 is Ki except
in the events of tight binding (Ki<< [E]) and small Km value (Km<< [S]). As IC50 will never
get below [E]/2, appropriate enzyme concentration is paramount for detecting tightly bound
ligands. The sudden drop in % of inhibition as inhibitor concentration drops from 100 to 10
nM in S3 Fig (Panel A) indicates bovine trypsin has a high affinity for the substrate Boc-
VPR-AMC i.e. small Km. Due to the potential flaws in IC50 values, it is a common practice in
early stage drug discovery to validate hits by orthogonal assays and determine the true Kd of
optimized lead molecules using standard techniques such as ITC. Interestingly, a recent report
has determined the ITC Kd of native SFTI for bovine trypsin to be 7-13nM [40], which under-
lines the fact that assay values can differ greatly depending on the assay conditions and mea-
surement technique used.
Substitution made on position 10 and 12 of the SFTI-1 sequence has brought universal
reduction (I10H) or augmentation (Analogue 2) in enzyme inhibition. As shown in Fig 1 Panel
A, only half of the surface of SFTI-1 is in direct contact with the enzyme, and both position 10
and 12 are on the non-contacting side. Changing residues in those positions are likely to have a
global effect on the SFTI-1 scaffold, possibly in the forms of ligand rigidity and hydrophobicity.
On the other hand, changing residue on position 5 i.e. the P1 residue [41] in the contacting
side will confer selectivity to the ligand. This is commonly known, but the inhibition of plasmin
and KLK7 by Analogue 2 and 6 have exemplified that even a minor change such as from lysine
to arginine could bring significant selectivity changes.
Not only can Analogue 6 inhibit KLK7, it inhibits KLK5 and 14 more potently than KLK8,
matriptase and plasmin. Since the degradation of the corneodesmosome involves the activity of
KLK5, KLK7 and KLK14, a multiple kallikrein inhibitor could be the optimal drug for therapy
of disease of this process, imitating the endogenous protease LEKTI. This is congruent with a
recent patent application [42] that emphasized the importance of multiple protease inhibition
(KLK5, 7, 14 and elastase) for NS treatment demonstrated by mice knockouts. Many studies
have also shown enhanced expression/activity of KLK5 and 7 in other skin conditions includ-
ing atopic dermatitis [43, 44], rosacea [45] and psoriasis [46]. The dual inhibition of KLK5 and
7 afforded by Analogue 6 may also be beneficial for those conditions.
It is known that LEKTI, the endogenous skin kallikreins inhibitor is able to inhibit KLK5
(tryptic), KLK7 (chymotryptic) and elastase [47] due to its multiple protein domains. Multiple
and simultaneous inhibitions of proteases from different family are considered a privilege of
protein protease inhibitors. Another example is the 71 amino acids Bowman-Birk inhibitor
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(BBI), a bifunctional trypsin-chymotrypsinprotein protease inhibitor found in soybean [48].
Its simultaneous, independent and potent inhibition of trypsin and chymotrypsin [49] is
achieved through two reactive loops in different regions of the protein. Having a lysine as the
P1 residue makes one loop inhibit trypsin and a leucine P1 residue on the other loop confers
chymotrypsin inhibition [50]. Though phylogenetically unrelated to BBI [51], SFTI-1 shares
strong sequence and structural homology with the BBI reactive loops and is specialized for
trypsin inhibition.We have shown here that it is possible to engineer a bifunctional SFTI-1
derived protease inhibitor by substituting the P1 residue lysine to arginine. Although there are
previous reports of SFTI-1 variants (containing a P1 arginine) that inhibited KLK5 and KLK7
[23, 39, 52, 53], the dual inhibition property could not be definitively attributed to P1 arginine
becausemultiple substitutions at different positions were also introduced whilst the effect of
each individual substitution was not characterized.Due to the small size of SFTI-1, it is how-
ever unlikely to afford the simultaneous inhibition of trypsin and chymotrypsin seen with BBI.
We have also demonstrated that the inhibitory effect of substitutions at different positions
of a cyclic peptide is additive with the increased inhibition of KLK5 and KLK7 by Analogue
6. For KLK7 inhibition, which is further enhanced by the F12W substitution, the K5R substi-
tution is the primary contributor. However, changing from lysine to arginine is not some-
thing one would expect to make a good chymotrypsin inhibitor, though an asparagine
residue is found in the substrate specificity pocket of KLK7. Although the fundamental effect
of the P1 arginine for dual inhibition remain to be elucidated fully, a trifunctional BBI variant
(76 residues) [54] also found in soybean highlights its importance. The variant was able to
inhibit trypsin, chymotrypsin and elastase via its two inhibitory loops. Favorably, the tryp-
sin-chymotrypsin inhibition was shared on one of the loop and the P1 residue was an
arginine.
After a buildup of structure activity relationship in Table 3, we characterized the thermody-
namic binding properties of I10H, Analogue 1, 2 and 6 to KLK5 by ITC. Under the test condi-
tions (1xPBS pH 8.0 at 25°C), the binding of all the tested SFTI-1 analogues to KLK5 was
endothermic. This is an interesting contrast to the binding of native SFTI with bovine trypsin,
which was found to be exothermic [40] albeit the two serine proteases share a highly conserved
structural scaffold. A small positive enthalpy (ΔH) but large positive entropy (ΔS) change
implies their binding was predominantly entropically driven. Compared to that of I10H, Ana-
logue 2 has a more positive ΔS value but a twofold increase in ΔH. It is likely to have displaced
additional water molecules as the larger tryptophan ring comes to close contact with residues
in the green region of Fig 2. In contrast, the ΔH of Analogue 1 is halved to that of I10H while
the ΔS remained essentially the same. This implies additional bond formation, resulted by a
change from lysine to arginine. A plausible scenario is that the guanidine group has formed
double hydrogen bonds with the aspartate of KLK5 at the substrate binding pocket (magenta
region, Fig 2).
To follow, we tested the ability of native SFTI and its analogues to suppress the proinflam-
matory PAR-2 signaling activation by KLK5 utilizing a cell-based assay. The assay detects
intracellular calciummobilization, as a result of PAR-2 activation by measuring fluorescence
changes. The fluorescence peak induced by KLK5 compared to PAR-2 agonist had a similar
peak time at around 40 seconds, but returned to baselinemuch more slowly. Their slight fluo-
rescence peak shape variation could be explained by the tethered ligand mechanism with
regards to the maximum rate of PAR-2 activation. KLK5 activation of PAR-2 is a twostep con-
tinuous process involving the cleavage and diffusion of the tethered ligand, but a one-step one-
off diffusion process for direct PAR-2 agonist injection.
With regards to the biological function of the SFTI-1 analogues, we further investigated the
ability of Analogue 6 to control IL-8 release from N-tert cells stimulated by KLK5 via the PAR-
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2 signaling pathway. At an inhibitor-to-enzyme ratio of 5:1, Analogue 6 was able to delay the
KLK5-induced IL-8 release by up to 6 hours but not for 24 hours. The short-lived effect could
be a result of selective cellular uptake of Analogue 6 thus allowing the KLK5 to activate PAR-2.
The presence of secreted reductasemay also break the disulfide bond of Analogue 6, which will
make the inhibitor to becomemore susceptible to protease attacks. Furthermore, we topically
applied Analogue 6 to a piece of in vitro grown skin and found it has dampened skin protease
activity beneath the cornified layer. Although the skin barrier generated from in vitro skin
equivalent culture is more permeable than normal human skin in vivo, the results nevertheless
demonstrated the potential efficacy of SFTI-1 derived topical drugs to control skin protease
activity.
In summary, we have discovered a novel bifunctional SFTI-1 variant that shows selective
and improved inhibition of multiple skin kallikreins.We were able to produce the variant in
good yield and its biological effectivenesswas validated by a comprehensive follow-up study
using biophysical technique, cell-based assay, in vitro cell and skin equivalent culture models.
This lead could be further developed to mimic the inhibitory fingerprint of LEKTI in the skin
for the treatment of NS and potentially more common skin disorders involving skin kallikreins
hyperactivity.
Materials and Methods
Synthesis of SFTI-1, SFTI I10H, and I10H Analogues
All linear peptide precursors were made by Fast-Moc™ chemistry on an ABI433A automated
peptide synthesizer. Solid-phase peptide synthesis was performed using standard Fmoc
amino acids and pre-loaded Fmoc-Cys (Trt)-NovaSyn1TGT resin. With 10 equivalents of
each amino acid, coupling reaction was initiated using 0.45 M N,N,N0,N0-Tetramethyl-O-
(1H-benzotriazol-1-yl)uroniumhexafluorophosphate and 0.45 M 1-Hydroxybenzotriazole
hydrate in dimethylformamide. 1.7 equivalent of N,N-diisopropylethylamine in N-methyl-
2-pyrrolidone was subsequently added. Fmoc deprotection was achieved by 20% volume to
volume (v/v) piperidine in N-methyl-2-pyrrolidone. The assembled peptide was cleaved in v/
v 95% trifluoroacetic acid, 2.5% 1, 2-ethanedithiol and 2.5% H2O at room temperature with
stirring for 4 hours. The resins were then removed by filtration and the peptide in solution
was precipitated by diethyl ether. The precipitated peptide was extracted by centrifugation at
2000 g for 15 minutes and then purified by reverse-phase high pressure liquid chromatogra-
phy (RP-HPLC).
RP-HPLC was performed in Dionex Ultimate 3000 system connected to a Phenomenex
Jupiter 10 μm Proteo 90 Å, C12 column (250x21.2 mm). Separations were carried out with a
gradient of increasing % of acetonitrile from 5–60% with 0.1% trifluoroacetic acid (v/v). The
purified linear peptide was lyophilized, weighted and reconstituted in water. The linear peptide
(1 mg/mL) was cyclized in the solution of 0.1 M sodium phosphate buffer (pH 5.8) and 0.7 M
sodium 2-mercaptoethane sulfonate. The reaction was left on for 48 hours at 55°C with stir-
ring. The cyclized peptide was purified by RP-HPLC then directly oxidized with addition of
ammonium bicarbonate (pH 8.0) at final concentration (f/c) of 50 mM. The oxidized cyclic
peptide was lyophilized and re-purified by RP-HPLC. The purified final product was lyophi-
lized and weighted. Quality of each compound was assured by analytical liquid chromatogra-
phy and mass spectrometry (Waters ACQUITYUPLC SQD) with an ACQUITY BEH C18
column (2.1x50 mm). The mobile phase was an increasing gradient of acetonitrile with 0.1% v/
v formic acid. RP-HPLC chromatogram and mass spectrumof each prepared compound are
available in S1 File.
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Protease Inhibition Assays
General procedures. All assays were performed on 96-well microplates and the change in
relative fluorescence unit (RFU) was measured by fluorescence spectrometer (BMG FLUOstar
OPTIMA). The excitation/emission wavelength was 360/460 nm for the substrate Boc-
VPR-AMC (BachemAG, Hauptstrasse, Switzerland) and MeOSuc-AAPV-AMC (BachemAG,
Hauptstrasse, Switzerland) and 485/520 nm for BODIPY_FL casein (Invitrogen, Carlsbad,
US). Stock solution of Boc-VPR-AMCwas prepared by dissolving the solid in dimethyl sulfox-
ide to 100 mM and 10 mM for MeOSuc-AAPV. For BODIPY_FL casein, it was reconstituted
to 1 mg/mL in 1xPBS. Ligand only and enzyme only were served as the negative (100% inhibi-
tion, Minimum RFU) and positive (0% inhibition,Maximum RFU) control respectively. The %
of inhibition was calculated by the following equation:
% of Inhibition ¼ 1  
ðSample RFU   Min RFUÞ
ðMax RFU   Min RFUÞ
 
X100
Each inhibition curveswere done in triplicates with a minimum of five concentration points
fitted. Fitting of each curvewas done using SigmaPlot with the Four Parameter Logistic Func-
tion and the IC50 calculated. Average of the three calculated IC50 values of each tested com-
pound with the standard deviation are used for Tables 2 and 3 and S1 Table. All tested
compounds were reconstituted to stock solution in water.
Enzyme activations by removal of N-terminal zymogen sequences. Recombinant KLK7,
KLK8 and KLK14 (>95% purity by SDS-PAGE, endotoxin<0.1 ng/μg, R&D, Minneapolis, U.
S.) stocks were diluted with 1xPBS to a concentration of 120 nM. KLK7 and KLK14 were acti-
vated by addition of 1 mM f/c CaCl2 (Sigma, Dorset, U.K.), 0.05% v/v Brij35 (Sigma, Dorset, U.
K.), 20 nM f/c thermolysin (Sigma, Dorset, U.K.) and incubated at 37°C for 1 hour. The reac-
tion was stopped by addition of ethylenediaminetetraaceticacid (EDTA, 50 mM f/c). KLK8
was activated by addition of 11 nM f/c lysyl endopeptidase (Santa Cruz Biotechnology, Dallas,
U.S.) and incubation at 37°C for 0.5 hour. The negative controls (no KLK) for the thermolysin
and lysyl endopeptidase activation mix confirmed that the two enzymes do not increase the
RFU whenmixed with Boc-VPR-AMC. Thermolysin had some residual activity against BODI-
PY_FL casein accounting for15% of the total cleavage activity. The RFU value reached by
the thermolysin control was used as the minimum RFU for calculating the % of inhibition for
KLK7.
S1 Table. The diluent for all the tested compounds, protein and substrate was 1xPBS pH
8.0. Zinc sulfate and p-aminobenzamidinewere purchased from Sigma (Dorset, U.K.). Serially
diluted ligands were mixed with 10 nM f/c recombinant KLK5 (>95% purity by SDS-PAGE,
endotoxin<0.1 ng/μg, Novoprotein, New Jersey, U.S.). The ligand-protein mixtures were incu-
bated on ice for 15 minutes and 20 μL was transferred to a well of a 96-well microplate (Ther-
moScientific,Waltham, U.S.) in triplicate. To start the reaction, 100μL of the diluted (41.6 μM
f/c) Boc-VPR-AMC substrate solution (contained 0.05% v/v Brij35) pH 8.0 was added. Change
in RFU was measured 15 minutes after substrate addition at 25°C.
Table 2. The diluent for all the tested compounds, protein and substrate was 1xPBS. Seri-
ally diluted ligands were mixed with diluted recombinant KLK5 (10 nM f/c). The ligand-pro-
tein mixtures were incubated on ice for one hour and 19.5 μL was pipetted into a well of a
96-well microplate in triplicates. To start the reaction, 100 μL of the diluted (41.6 μM f/c) Boc-
VPR-AMC substrate solution (contained 0.05% v/v Brij35) was added. The plate was incubated
at 37°C and the RFU reading was taken 15 minutes after.
Table 3. The diluent for all the tested compounds, protein and substrate (except KLK7,
which was done with 10 mMTris pH 7.8) was 1xPBS pH 8.0–8.9. The serially diluted ligands
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were mixed with diluted bovine trypsin (Sigma, Dorset, U.K.) or activated KLK14, or KLK5, or
activated KLK8 or matriptase (catalytic domain only, >90% purity by SDS-PAGE, endotoxin
<0.1 ng/μg, R&D, Minneapolis, U.S.) or activated KLK7 or human neutrophil elastase (puri-
fied from human plasma,>95% purity by SDS-PAGE, Abcam, Cambridge, U.K.) or porcine
pancreatic elastase 1 (Sigma, Dorset, U.K.) or human plasma kallikrein or human plasma plas-
min (purified from human plasma,95% purity by SDS-PAGE, BioVision, Milpitas, U.S.).
20μL of the ligand-protein mixture was pipetted to a well of a 96-well microplate in triplicates.
The reaction was started by addition of 90–100 μL of the diluted substrate solution (contained
0.05% v/v Brij35) and the plate incubated at 25°C but 37°C for KLK7. RFU reading for each
well was taken 6 minutes (trypsin) or 15 minutes (KLK14, KLK5, KLK8, matriptase, human
neutrophil elastase, porcine pancreatic elastase 1, plasma kallikrein and plasmin) or 20 hours
(KLK7) after substrate addition.
Calculationof Ki from IC50. There are two previously reported Km values [52, 55] for
KLK5 and its substrate Boc-VPR-AMCwhich allowed the IC50 to Ki conversion. Ki values
were calculated according to the Cheng-Prusoff [56] equation Ki ¼ IC50
1þ½S=Km
for single site com-
petitive binding.
Isothermal Titration Calorimetry
ITC experiments were performedon a MicroCal iTC200 calorimeter (GE Healthcare, Uppsala,
Sweden) at 298.15 K with a stirring speed of 750 revolutions per minute. Concentrated (450 μM)
ligand solutions were injected into protein (KLK5) solution (20 μM, 280 μL sample volume) in
the sample cell. Injection volumes were 2 μL for I10H and Analogue 1 and 1 μL for Analogue 2
and 6 with a spacing of 120 seconds between each injection. Concentrations of ligands were
determined by dried weight and they were reconstituted to 10 mM stock in H2O. Concentration
of KLK5 was determined by UV280 calculatedwith an extinction coefficient of 38680 and
molecularweight of 32KDa (including weight of glycosylation). The protein solution were buffer
exchanged using spin column to 1xPBS (137 mMNaCl, 2.7 mMKCl, 4.3 mMNa2HPO4, 1.47
mMKH2PO4 pH 8.0) or 20 mMMES buffer (with 150 mMNaCl, pH 5.5). Ligand stocks were
diluted in those buffers (4.5 μL + 95.5 μL buffer), and then equal v/v % of H2O was added to the
protein solution after buffer exchange to ensure matching buffer contents. Heat of dilution was
undetectable in control experiments. Data were analyzed using OriginLabversion 7.0.
Cell Culture
Keratinocyte cell line N-tert cells [57], a gift from Professor David Kelsell’s lab (QueenMary
University of London) were cultured in keratinocytes culture medium (RM+) [58]. The media
contained equal amount of DMEM and DMEM/Ham F12 (Life Technologies, Paisley, UK)
supplemented with 10% fetal calf serum (Labtech, East Sussex, UK), 100 IU/ml of penicillin
and 100 μg/ml of streptomycin (Life Technologies, Paisley, UK). Human keratinocyte growth
supplement was then added to the media at final concentrations of 10 ng/ml of epidermal
growth factor (Bio-RadAbD Serotec, Oxford, UK), 0.4 μg/ml of hydrocortisone, 5 μg/ml of
transferrin, 5μg/ml of insulin, 2x10-11 M of liothyronine and 1x10-10 M of cholera toxin
(Sigma, Dorset, UK). Fibroblasts were cultured in DMEM supplemented with 10% fetal calf
serum, 100 IU/ml of penicillin and 100 μg/ml of streptomycin
Intracellular Calcium Mobilization Assay
24 hours prior to the assay, the immortalized keratinocyte cell line N-tert was detached from
the culture flask by 0.25% trypsin/EDTA (Life Technologies, Paisley, UK) and resuspended in
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fresh RM+medium. The cells were counted and 100 μL of the suspension was seeded to the
wells of a 96-well microplate at the density of 590,000 cells/mL. The plate of cells was incubated
at 37°C 10% CO2 until assay. On the day of the assay, the dye loading solution was prepared
according to manufacturer’s instruction (FLUOFORTE1 ENZO Life Sciences, Farmingdale,
U.S.). The culture mediumwas discarded and replaced with 100 μL of dye loading solution.
The plate was incubated at 37°C for one hour. 5 μL of PAR-2 agonist peptide (Bachem AG,
Hauptstrasse, Switzerland) were injected to show the presence of operational PAR-2 receptors.
The native SFTI and its analogues were serially diluted with 1xPBS and mixed with purified
recombinant KLK5. 5 μL of the ligand-protein mixture was injected and the change in fluores-
cence (Ex485/Em520 nm) was monitored every 8 seconds at 37°C. The orbital averaging (3mm
diameter) function of the plate reader (BMG FLUOstar OPTIMA, Ortenberg,Germany) was
used to compensate for heterogeneous distribution of cells in each well.
KLK5 Induced IL-8 Secretion and ELISA
Two days prior to addition of recombinant KLK5, 100 μL of N-tert skin cells suspension (den-
sity = 604,000 cells/mL)were seeded to each well of a 96-well cell culture plate in RM+medium.
The culture mediumwas changed to serum-free (SF) RM+medium 24 hours later and the cells
further incubated overnight for equilibration. The 0hr pre-treatment samples were first taken
by drawing the cell medium after the overnight SF incubation. 20 μL of fresh SF RM+ was
added to each pre-treatment sample. Using SF RM+ as the diluent, five different solutions were
prepared giving five different treatment groups. These are Medium Only (SF RM+ as is), KLK5
Only (diluted KLK5 f/c 300 nM), KLK5 + Analogue 6 (mixture of Analogue 6 f/c 1515 nM and
KLK5 f/c 300 nM), Analogue 6 Only (diluted Analogue 6 f/c 1515 nM), and Medium + 0.2 mM
MES (dilutedMES f/c 0.2 mM). The solutions were incubated at 37°C for 15 minutes, and then
in the form of a 3x3 matrix, 20μL of each of the solution was added separately to a well of cells
in the 96-well plate. Samples were taken at 6, 24 and 48 hours after. The 48hr untreated sam-
ples were then taken by drawing the medium from untreated cells that had been growing 48hr
after the treatment. 20 μL of fresh SF RM+was added to each 48hr untreated sample. All sam-
ples were collected and frozen immediately at -80°C until use. IL-8 level in each collected sam-
ple was determined using enzyme-linked immunosorbent assay kit (eBioscience 88-8086-22).
IL-8 level of each treatment group at different time points were analyzed by one-way analysis
of variance with Tukey’s honest significant difference post hoc.
Organotypic Skin Culture (OTC) and in-situ Zymography
Primary keratinocytes and fibroblasts were isolated from skin biopsies from healthy donors
and incubated with 0.25% trypsin/EDTA 3 hours for keratinocytes and Serva 50U/ml collage-
nase NB6 (Universal Biologicals, Cambridge, UK) 2 hours for fibroblasts. Isolated primary ker-
atinocytes were then co-culturedwith lethally irradiated 3T3 mouse fibroblasts and grown in
keratinocyte culture media. Primary keratinocytes and fibroblasts from normal donors’ skin
biopsies were cultivated in vitro on de-epidermalizeddermal matrix as described [59]. Briefly,
dermal fibroblasts derived from skin biopsies were seeded onto the reticular side of the de-epi-
dermalized dermal matrix and keratinocytes were seeded on the papillary side. After keratino-
cytes reached confluence, the culture was lifted at the air-liquid interface for 14 days. The
OTCs were then topically treated with Analogue 6 (10 μL, 10 μM) or 1xPBS for the untreated
control in two doses each separated by 24hrs. Following treatment, the cultures were harvest
and embedded in O.C.T.™ (Sakura Finetek, Netherlands) for cryosections.The cryosections
(7 μm thick) of the treated and untreated tissues were washed with 1xPBS. BODIPY_FL casein
(Invitrogen, Carlsbad, US) substrate solution was prepared according to manufacturer’s
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instruction and applied to the skin sections. As for the negative control, 1xPBS was applied
instead. The sections were incubated at 37°C overnight in the dark with maintained humidity.
They were washed with 1xPBS the next day and counterstained with 4',6-diamidino-2-pheny-
lindole for 2 minutes. After the final soak in 1xPBS containing 0.1% TritonX-100 for 20 min-
utes, the air dried tissues were mounted with ProLong1 Diamond Antifade Mountant (Life
Technologies, Paisley, U.K.). Sectionswere examined under a Leica DM LB fluorescence
microscope and the images processed using ImageJ (v1.46).
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Supporting Information
S1 Fig. Fitted KLK5 Inhibition IC50 Curves. IC50 curves of KLK5 inhibition including error
bars (standard deviation) of each repeated reading (N = 3) for native SFTI, I10H, p-aminoben-
zamidine, and zinc sulfate are shown.
(TIF)
S2 Fig. Fitted KLK5 Inhibition IC50 Curves. IC50 curves of KLK5 inhibition including error
bars (standard deviation) of each repeated reading (N = 3) for I10H and Analogue 1–4 are dis-
played.
(TIF)
S3 Fig. Fitted IC50 Curves of Various Serine Proteases. Fitted IC50 curves including error
bars (standard deviation) of each repeated reading (N = 3) for Native SFTI, I10H, Analogue 1,
2 and 6 against bovine trypsin(A), KLK14 (B), KLK8 (C), matriptase (D. catalytic domain
only), KLK7 (E) or human plasmin (F) are displayed.
(DOCX)
S4 Fig. IntracellularCalciumMobilization Stimulated by PAR-2 Agonist Peptide. Change
in fluorescencewas measured over time after injection of a PAR-2 agonist peptide
(H-SLIGKV-NH2) into a well of a 96-well cell culture plate with cells at the bottom of the plate
covered in a calcium-binding dye solution. The cells used were of the keratinocyte cell line N-
tert. The plot is from the averaged values of two repeated runs.
(TIF)
S1 File. RP-HPLC, Liquid Chromatography andMass Spectrometryof Each Prepared
Compound.The RP-HPLC chromatogram of the final purification stage for each prepared
compound is shown. The collected final product illustrated by the red rectangle was then sub-
jected to liquid chromatography and mass spectrometry analysis prior to freeze dry. Total ion
count and mass spectrumof the detected peak are shown below.
(DOCX)
S1 Table. Inhibition of KLK5 by Native SFTI, I10H, p-aminobenzamidineand Zinc.
(DOCX)
S2 Table. ThermodynamicBinding Parameters of I10H and Its Analogues for KLK5 at
25°C.
(DOCX)
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